• Myeloma Clinical Trials
    • Jan 07, 2017

    Clinical Trial: Daratumumab, Cytoxan, Dex and Velcade for Newly Diagnosed and Relapsed Myeloma

Daratumumab is now being used in many clinical trials in many different combinations. Because of its success in past clinical trials, it is moving to earlier use (in studies) for both newly diagnosed patients and at first relapse.

According to Torben Plesner, MD in a recent Myeloma Crowd Radio show , daratumumab shows interesting results when effectively combined with cyclophosphamide (Cytoxan).

This study will evaluate responses (complete response and very good partial response) for newly diagnosed and relapsed patients. The study combination will include four drugs: daratumumab, cyclophosphamide, dexamethasone and bortezomib.

The study is open in 32 locations. To learn more, click the button below.

Dara with CyborD Clinical Trial

About Author

Jenny A

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

MYELOMA CROWD RESEARCH INITIATIVE
$49,561 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal

Get Started Today.

Find a Clinical Trial that's Right for You

Thanks to our site sponsors: